Serious adverse events
|
NIVOLUMAB 3 MG/KG IV |
Total subjects affected by serious adverse events
|
|
subjects affected / exposed
|
593 / 1008 (58.83%) |
number of deaths (all causes)
|
527 |
number of deaths resulting from adverse events
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
Adenocarcinoma
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Adenocarcinoma of colon
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Anal neoplasm
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Basal cell carcinoma
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Bowen's disease
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Breast cancer
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cancer pain
|
|
subjects affected / exposed
|
5 / 1008 (0.50%) |
occurrences causally related to treatment / all
|
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
Chronic lymphocytic leukaemia
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Infected neoplasm
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Intracranial tumour haemorrhage
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Malignant ascites
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Malignant melanoma
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Malignant neoplasm of spinal cord
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Malignant neoplasm progression
|
|
subjects affected / exposed
|
278 / 1008 (27.58%) |
occurrences causally related to treatment / all
|
0 / 310 |
deaths causally related to treatment / all
|
0 / 239 |
Melanoma recurrent
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to abdominal cavity
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to adrenals
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to bladder
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to bone
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to central nervous system
|
|
subjects affected / exposed
|
16 / 1008 (1.59%) |
occurrences causally related to treatment / all
|
0 / 16 |
deaths causally related to treatment / all
|
0 / 1 |
Metastases to liver
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to lung
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to meninges
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to peritoneum
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
Metastases to skin
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Metastases to spine
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metastasis
|
|
subjects affected / exposed
|
5 / 1008 (0.50%) |
occurrences causally related to treatment / all
|
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Metastatic malignant melanoma
|
|
subjects affected / exposed
|
15 / 1008 (1.49%) |
occurrences causally related to treatment / all
|
0 / 18 |
deaths causally related to treatment / all
|
0 / 1 |
Neoplasm
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pituitary tumour benign
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Renal cell carcinoma
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Squamous cell carcinoma
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Squamous cell carcinoma of skin
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Tonsil cancer
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Tumour associated fever
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Tumour flare
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
3 / 3 |
deaths causally related to treatment / all
|
1 / 1 |
Tumour haemorrhage
|
|
subjects affected / exposed
|
8 / 1008 (0.79%) |
occurrences causally related to treatment / all
|
0 / 8 |
deaths causally related to treatment / all
|
0 / 1 |
Tumour necrosis
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Non-Hodgkin's lymphoma
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Tumour pain
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Vascular disorders
|
|
Angiopathy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Circulatory collapse
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Deep vein thrombosis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Embolism
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Extremity necrosis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hypertension
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Hypertensive crisis
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Hypotension
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
1 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Jugular vein thrombosis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Lymphoedema
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Peripheral venous disease
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Superior vena cava syndrome
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Thrombosis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Vascular occlusion
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Lymphocele
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pregnancy, puerperium and perinatal conditions
|
|
Pregnancy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
General disorders and administration site conditions
|
|
Asthenia
|
|
subjects affected / exposed
|
5 / 1008 (0.50%) |
occurrences causally related to treatment / all
|
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Chest pain
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Disease progression
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Fatigue
|
|
subjects affected / exposed
|
7 / 1008 (0.69%) |
occurrences causally related to treatment / all
|
4 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
General physical health deterioration
|
|
subjects affected / exposed
|
22 / 1008 (2.18%) |
occurrences causally related to treatment / all
|
0 / 25 |
deaths causally related to treatment / all
|
0 / 5 |
Generalised oedema
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Malaise
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Nodule
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Oedema peripheral
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Pyrexia
|
|
subjects affected / exposed
|
9 / 1008 (0.89%) |
occurrences causally related to treatment / all
|
2 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
Sudden death
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
1 / 3 |
deaths causally related to treatment / all
|
1 / 3 |
Treatment failure
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Multiple organ dysfunction syndrome
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 2 |
Pain
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Immune system disorders
|
|
Anaphylactic shock
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Autoimmune disorder
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Contrast media allergy
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Drug hypersensitivity
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Reproductive system and breast disorders
|
|
Ovarian cyst ruptured
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pelvic pain
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Penile oedema
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Testicular oedema
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Vaginal haemorrhage
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Respiratory, thoracic and mediastinal disorders
|
|
Acute respiratory failure
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
Aspiration
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Atelectasis
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Cough
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Dyspnoea
|
|
subjects affected / exposed
|
8 / 1008 (0.79%) |
occurrences causally related to treatment / all
|
0 / 9 |
deaths causally related to treatment / all
|
0 / 1 |
Haemoptysis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Interstitial lung disease
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Pleural effusion
|
|
subjects affected / exposed
|
9 / 1008 (0.89%) |
occurrences causally related to treatment / all
|
0 / 12 |
deaths causally related to treatment / all
|
0 / 0 |
Pneumonia aspiration
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
Pneumonitis
|
|
subjects affected / exposed
|
10 / 1008 (0.99%) |
occurrences causally related to treatment / all
|
10 / 10 |
deaths causally related to treatment / all
|
0 / 0 |
Pneumothorax
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pulmonary embolism
|
|
subjects affected / exposed
|
14 / 1008 (1.39%) |
occurrences causally related to treatment / all
|
0 / 14 |
deaths causally related to treatment / all
|
0 / 3 |
Pulmonary toxicity
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Respiratory failure
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Respiratory muscle weakness
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Psychiatric disorders
|
|
Confusional state
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
1 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Depression
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Personality change
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Schizophrenia
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Psychotic disorder
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Product issues
|
|
Device dislocation
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Investigations
|
|
Alanine aminotransferase increased
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
2 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Aspartate aminotransferase increased
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
1 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Blood creatinine increased
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
General physical condition abnormal
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
International normalised ratio increased
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Lipase increased
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Pancreatic enzymes increased
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Transaminases increased
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Csf test abnormal
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Gamma-Glutamyltransferase increased
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Troponin t increased
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Injury, poisoning and procedural complications
|
|
Accidental overdose
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Ankle fracture
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Craniocerebral injury
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Dose calculation error
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 13 |
deaths causally related to treatment / all
|
0 / 0 |
Fall
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Femoral neck fracture
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Femur fracture
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Fractured sacrum
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Joint dislocation
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Overdose
|
|
subjects affected / exposed
|
5 / 1008 (0.50%) |
occurrences causally related to treatment / all
|
4 / 20 |
deaths causally related to treatment / all
|
0 / 0 |
Procedural headache
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Radiation necrosis
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Radius fracture
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Spinal compression fracture
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Spinal fracture
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Subdural haematoma
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Ulna fracture
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hip fracture
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pubis fracture
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cardiac disorders
|
|
Acute coronary syndrome
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Acute myocardial infarction
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Angina pectoris
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Atrial fibrillation
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Atrial flutter
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cardiac failure
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cardiopulmonary failure
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Coronary artery occlusion
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Ischaemic cardiomyopathy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Myocardial infarction
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Myocarditis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pericardial effusion
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Coronary artery disease
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Coronary artery insufficiency
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Supraventricular tachycardia
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cardio-Respiratory arrest
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Nervous system disorders
|
|
Altered state of consciousness
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Aphasia
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Brachial plexopathy
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Brain injury
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Brain oedema
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Brain stem haemorrhage
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Central nervous system lesion
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cerebral haematoma
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cerebral haemorrhage
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Cerebrovascular accident
|
|
subjects affected / exposed
|
7 / 1008 (0.69%) |
occurrences causally related to treatment / all
|
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
Encephalopathy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Epilepsy
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Facial paralysis
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Facial paresis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Haemorrhage intracranial
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 2 |
Headache
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
1 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Hemiparesis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hepatic encephalopathy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hypertensive encephalopathy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Lumbar radiculopathy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Myasthenia gravis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Narcolepsy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Nervous system disorder
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Peripheral nerve lesion
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Peripheral sensorimotor neuropathy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Polyneuropathy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Seizure
|
|
subjects affected / exposed
|
6 / 1008 (0.60%) |
occurrences causally related to treatment / all
|
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
Sensorimotor disorder
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Spinal cord compression
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 1 |
Status epilepticus
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Syncope
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Diabetic hyperosmolar coma
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Generalised tonic-clonic seizure
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Lethargy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Neurological decompensation
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Sciatica
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Miller fisher syndrome
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Blood and lymphatic system disorders
|
|
Anaemia
|
|
subjects affected / exposed
|
10 / 1008 (0.99%) |
occurrences causally related to treatment / all
|
1 / 12 |
deaths causally related to treatment / all
|
0 / 0 |
Haemorrhagic anaemia
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Thrombocytopenia
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Ear and labyrinth disorders
|
|
Vertigo
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Eye disorders
|
|
Ectropion
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Iridocyclitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Iritis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Macular hole
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Ulcerative keratitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Uveitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Vision blurred
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Retinal detachment
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Vitreous haemorrhage
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Gastrointestinal disorders
|
|
Abdominal pain
|
|
subjects affected / exposed
|
13 / 1008 (1.29%) |
occurrences causally related to treatment / all
|
0 / 13 |
deaths causally related to treatment / all
|
0 / 0 |
Ascites
|
|
subjects affected / exposed
|
5 / 1008 (0.50%) |
occurrences causally related to treatment / all
|
1 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
Autoimmune colitis
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
1 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Autoimmune pancreatitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Colitis
|
|
subjects affected / exposed
|
7 / 1008 (0.69%) |
occurrences causally related to treatment / all
|
6 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
Colitis ischaemic
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Constipation
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Diarrhoea
|
|
subjects affected / exposed
|
14 / 1008 (1.39%) |
occurrences causally related to treatment / all
|
12 / 16 |
deaths causally related to treatment / all
|
0 / 0 |
Dyspepsia
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Food poisoning
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Gastritis
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Gastrointestinal haemorrhage
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Ileal perforation
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Inguinal hernia
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Intestinal fistula
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Intestinal obstruction
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Intussusception
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Large intestinal obstruction
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Melaena
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Nausea
|
|
subjects affected / exposed
|
8 / 1008 (0.79%) |
occurrences causally related to treatment / all
|
4 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
Oesophagitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pancreatitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pancreatitis acute
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Rectal haemorrhage
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Small intestinal obstruction
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Small intestinal perforation
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Stomatitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Upper gastrointestinal haemorrhage
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Vomiting
|
|
subjects affected / exposed
|
10 / 1008 (0.99%) |
occurrences causally related to treatment / all
|
3 / 12 |
deaths causally related to treatment / all
|
0 / 0 |
Anal haemorrhage
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Gastrointestinal disorder
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Gastrooesophageal reflux disease
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Ileus
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Subileus
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hepatobiliary disorders
|
|
Autoimmune hepatitis
|
|
subjects affected / exposed
|
8 / 1008 (0.79%) |
occurrences causally related to treatment / all
|
8 / 8 |
deaths causally related to treatment / all
|
1 / 1 |
Cholecystitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Cholelithiasis
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Hepatic failure
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Hepatic function abnormal
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hepatic pain
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Hepatomegaly
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hypertransaminasaemia
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Jaundice
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Jaundice cholestatic
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Liver disorder
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Immune-Mediated hepatitis
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
5 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Skin and subcutaneous tissue disorders
|
|
Dermatitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Dermatitis exfoliative
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Drug eruption
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Erythema
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Generalised erythema
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pemphigoid
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Pruritus generalised
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Rash generalised
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Rash maculo-papular
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Skin ulcer
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Erythema multiforme
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Rash macular
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Renal and urinary disorders
|
|
Acute kidney injury
|
|
subjects affected / exposed
|
9 / 1008 (0.89%) |
occurrences causally related to treatment / all
|
3 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
Autoimmune nephritis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Bladder pain
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hydronephrosis
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
Nephrolithiasis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Postrenal failure
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Renal failure
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
1 / 4 |
deaths causally related to treatment / all
|
0 / 3 |
Renal impairment
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Tubulointerstitial nephritis
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
6 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
Ureteric stenosis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Urinary tract obstruction
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Urinary retention
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Endocrine disorders
|
|
Addison's disease
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Adrenal insufficiency
|
|
subjects affected / exposed
|
5 / 1008 (0.50%) |
occurrences causally related to treatment / all
|
4 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Autoimmune thyroiditis
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Hyperthyroidism
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hypophysitis
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
4 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Hypopituitarism
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
3 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Hypothyroidism
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
3 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Lymphocytic hypophysitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Secondary adrenocortical insufficiency
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Steroid withdrawal syndrome
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Adrenal haemorrhage
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Musculoskeletal and connective tissue disorders
|
|
Arthralgia
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Arthritis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Back pain
|
|
subjects affected / exposed
|
8 / 1008 (0.79%) |
occurrences causally related to treatment / all
|
0 / 10 |
deaths causally related to treatment / all
|
0 / 0 |
Bone pain
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Fistula
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Flank pain
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Groin pain
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Mobility decreased
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Muscular weakness
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Musculoskeletal chest pain
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Myositis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Osteoarthritis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Osteochondrosis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Tendonitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pain in extremity
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Infections and infestations
|
|
Abdominal infection
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
Abdominal sepsis
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Anal abscess
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Appendiceal abscess
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Appendicitis
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Arthritis bacterial
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Bronchitis
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Bronchopulmonary aspergillosis allergic
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Cellulitis
|
|
subjects affected / exposed
|
6 / 1008 (0.60%) |
occurrences causally related to treatment / all
|
0 / 11 |
deaths causally related to treatment / all
|
0 / 0 |
Conjunctivitis
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Cystitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Device related infection
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Device related sepsis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Diarrhoea infectious
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Enterocolitis infectious
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Erysipelas
|
|
subjects affected / exposed
|
7 / 1008 (0.69%) |
occurrences causally related to treatment / all
|
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
Escherichia urinary tract infection
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Gastroenteritis
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Haematoma infection
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Herpes zoster
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Infected dermal cyst
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Infected lymphocele
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Infection
|
|
subjects affected / exposed
|
5 / 1008 (0.50%) |
occurrences causally related to treatment / all
|
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
Infective exacerbation of chronic obstructive airways disease
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Influenza
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Latent tuberculosis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Lower respiratory tract infection
|
|
subjects affected / exposed
|
9 / 1008 (0.89%) |
occurrences causally related to treatment / all
|
0 / 12 |
deaths causally related to treatment / all
|
0 / 0 |
Lung infection
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Perirectal abscess
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pneumococcal sepsis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pneumonia
|
|
subjects affected / exposed
|
13 / 1008 (1.29%) |
occurrences causally related to treatment / all
|
1 / 14 |
deaths causally related to treatment / all
|
0 / 2 |
Pneumonia legionella
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pseudomembranous colitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Pyelonephritis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Respiratory tract infection
|
|
subjects affected / exposed
|
5 / 1008 (0.50%) |
occurrences causally related to treatment / all
|
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
Sepsis
|
|
subjects affected / exposed
|
8 / 1008 (0.79%) |
occurrences causally related to treatment / all
|
0 / 8 |
deaths causally related to treatment / all
|
0 / 1 |
Septic encephalopathy
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Sinusitis
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Soft tissue infection
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Tonsillitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Tooth abscess
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Tooth infection
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Tracheobronchitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Urinary tract infection
|
|
subjects affected / exposed
|
11 / 1008 (1.09%) |
occurrences causally related to treatment / all
|
0 / 13 |
deaths causally related to treatment / all
|
0 / 0 |
Urosepsis
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Vascular device infection
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Viral diarrhoea
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Viral infection
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Wound infection
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Gastroenteritis viral
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Gastrointestinal infection
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Meningitis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Septic shock
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
Tuberculosis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Upper respiratory tract infection
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metabolism and nutrition disorders
|
|
Cachexia
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Dehydration
|
|
subjects affected / exposed
|
4 / 1008 (0.40%) |
occurrences causally related to treatment / all
|
1 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
Diabetes mellitus
|
|
subjects affected / exposed
|
3 / 1008 (0.30%) |
occurrences causally related to treatment / all
|
2 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Hypercalcaemia
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hyperglycaemia
|
|
subjects affected / exposed
|
7 / 1008 (0.69%) |
occurrences causally related to treatment / all
|
4 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
Hyperkalaemia
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
2 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
Hypernatraemia
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Hypocalcaemia
|
|
subjects affected / exposed
|
2 / 1008 (0.20%) |
occurrences causally related to treatment / all
|
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
Hypoglycaemia
|
|
subjects affected / exposed
|
5 / 1008 (0.50%) |
occurrences causally related to treatment / all
|
1 / 6 |
deaths causally related to treatment / all
|
1 / 1 |
Hyponatraemia
|
|
subjects affected / exposed
|
6 / 1008 (0.60%) |
occurrences causally related to treatment / all
|
4 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
Hypoproteinaemia
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Ketoacidosis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Type 1 diabetes mellitus
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Decreased appetite
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
Metabolic acidosis
|
|
subjects affected / exposed
|
1 / 1008 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |